Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 7, 1999, Pages 2363-2368

  Ravn, P ^a   Hosking, D ^b   Thompson, D ^c   Cizza, G ^c   Wasnich, R D ^d   McClung, M ^e   Yates, A J ^c   Bjarnason, N H ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Hawaii Osteoporosis Center   (United States)

^e Center for Metabolic Bone Disorder   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; OSTEOCALCIN;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033306407     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.7.2363     Document Type: Article

References (25)

1. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
2. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial
3. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study
4. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss
5. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)
6. The prevention and treatment of osteoporosis
7. Noninvasive assessment of bone mineral and structure: State of the art
8. The coupling of bone formation to resorption: A critical analysis of the concept and its relevance to the pathogenesis of osteoporosis
9. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
10. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
11. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment
12. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
13. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
14. The response in spinal bone mass to tibotone treatment is related to bone turnover in elderly women
15. A specific immunoassay for monitoring human bone resorption: Quantitation of type 1 collagen cross-linked N-tetopeptides in urine
16. Serum osteocalcin and bone mineral density at various skeletal sites: A study performed with three different assays
17. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers
18. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodelling
19. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
20. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women
21. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine
22. Changes in BMD substantially underestimate the antifracture effect of alendronate and other antiresorptive drugs
23. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
24. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study
25. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12-year study